Lipids and endothelium are pivotal players on the scene of atherosclerosis and their interaction is crucial for the establishment of the pathological processes. The endothelium is not only the border of the arterial wall: it plays a key role in regulating circulating fatty acids and lipoproteins and vice versa it is regulated by these lipidic molecules thereby promoting atherosclerosis. Inflammation is another important element in the relationship between lipids and endothelium. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recognized as a fundamental regulator of LDL-C and anti-PCSK9 monoclonal antibodies have been approved for therapeutic use in hypercholesterolemia, with the promise to subvert the natural history of the disease. Moreover, growing experimental and clinical evidence is enlarging our understanding of the mechanisms through which this protein may facilitate the genesis of atherosclerosis, independently of its impact on lipid metabolism. In addition, environmental stimuli may affect the post-transcriptional regulation of genes through micro-RNAs, which in turn play a key role in orchestrating the crosstalk between endothelium and cholesterol. Advances in experimental research, with development of high throughput techniques, have led, over the last century, to a tremendous progress in the understanding and fine tuning of the molecular mechanisms leading to atherosclerosis. Identification of pivotal keystone molecules bridging lipid metabolism, endothelial dysfunction and atherogenesis will provide the mechanistic substrate to test valuable targets for prediction, prevention and treatment of atherosclerosis-related disease.
A Couple at the Beginning of Atherosclerosis: Endothelium and Lipids
Atherosclerosis is the result of complex pathogenic mechanisms initiated by the lipid-endothelium intertwining, eventually leading to the development of atherosclerotic plaques. The endothelium is characterized by intercellular tight junctions and represents a selectively permeable barrier. It has a duplex role, having both sensory and executive functions, and can also generate molecules thus influencing multiple processes such as vascular tone and remodeling, inflammation and thrombosis. A lot of different forces act on endothelial cells (EC), one being the fluid shear stress. In fact, where blood flow is uniform and laminar, cells are ellipsoid in shape and aligned in the direction of flow, showing elevated nitric oxide (NO) production, reduced oxidant stress, enhanced barrier function and limited proinflammatory activity, through Erk5-dependent expression of Klf2, which binds NF-κB and competes for binding of transcriptional coactivators. Vice versa, where flow is altered, cells have polygonal shapes without a particular orientation, showing an increased permeability to macromolecules, for example low-density lipoprotein cholesterol (LDL-C) [1] , reduced NO production and enhanced oxidant stress, endothelial turnover and proinflammatory activation. Moreover, exposure to laminar flow in culture actively suppresses endothelial activation by cytokines and oxidized LDL-C by hindering NF-кB-dependent proinflammatory gene expression and promoting NF-кB-dependent anti-apoptotic gene expression [2] . The accumulation of LDL-C in the subendothelial matrix is indeed one of the most important initiating events of atherosclerosis. The higher the LDL-C levels, the greater the accumulation: LDL diffuses passively through EC junctions and its retention in the vessel wall involves interactions between the LDL-C constituent apolipoprotein B (apoB) and matrix proteoglycans [3] .
However, atherosclerosis is not just a LDL-C-centered process: other apoB-containing lipoproteins, namely lipoprotein(a) and remnants, can also accumulate in the intima and promote atherosclerosis. In particular, lipoprotein(a) has been shown to be particularly atherogenic for its effects on fibrinolysis and smooth muscle cells (SMC) growth [4] .
A strong relationship exists between LDL-C and arterial wall: the LDL-C are somehow 'modified' in the vessel wall, undergoing oxidation, lipolysis, proteolysis and aggregation, thus contributing to inflammation as well as to foam-cell formation. Lipid peroxidation is one of the most significant modifications in terms of early lesion formation as a result of the exposure of vascular cells to oxidative stress stimuli, a combination of enzymatic, such as lipoxygenases, and non-enzymatic, free-radical catalyzed reactions. The main modification of LDL-C takes place inside the intima, where proteoglycans can sequester LDL-C [5] .
If endothelium influences lipids, their migration and modification, vice versa a large number of studies have shown an impairment of vasodilatation mediated by endotheliumderived NO in response to elevated total cholesterol and particularly LDL-C. LDL-C effects have been demonstrated at numerous sites of the NO signaling pathway including G-protein-coupled receptors, NO synthase (NOS) and NO bioactivity, with evidence for enhanced superoxide formation and the consequent production of the less potent dilator peroxynitrite. The effects of lipids on endothelium-dependent vasodilation can be reversed not only by reducing the level of lipids but also by provision of the NOS substrate, l-arginine and antioxidants, although the mechanisms underlying these effects are not fully elucidated [6] .
Lipids and endothelium do not represent the only protagonists on the scene: a lot of other actors can influence this relationship and modulate endothelial dysfunction. Platelets are an example of potential "influencers".
Interestingly, both platelet activation and endothelial dysfunction are early events in the natural history of atherosclerosis. A continuous dialogue exists between platelets and endothelial cells, dating back to the bone marrow, where haematopoietic precursors, megakaryocytes, and sinusoidal endothelium interact directly [7] . In addition, platelets are a source of oxygen free radicals, and trigger a cascade of events that ultimately leads to endothelial dysfunction: this process is supported by observations showing a progressive decrease in platelet formation of NO moving from patients with hereditary deficiency in gp91phox (NOX-2) to obese patients [8] .
NOX2 represents the catalytic core of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, that is believed to modulate arterial tone. In fact, vascular tone is modulated by NADPH oxidase-generated oxidative stress, affecting NO generation. Since platelets are a pivotal source of systemic NOX-2, it is conceivable that they are the initiators of this detrimental cascade in settings of persistently enhanced platelet activation, such as obesity and metabolic syndrome [9] .
The Lipids-Endothelium Couple and a Third Wheel: Inflammation
Inflammation is another important element in the relationship between lipids and endothelium. If macrophages play a fundamental role since the initial phases of the atherosclerotic process, thus participating to plaque progression, a staggering array of immune cells migrate into the plaque and release different kinds of cytokines contributing to a further progression or to a regression of the plaque. The cytokines associated with inflammatory macrophage and Th1 T cell responses, such as interferon-γ (IFN-γ), interleukin (IL)-1α, IL-1β, and tumor necrosis factor-α (TNF-α) are responsible for encouraging atherosclerosis and these pro-atherogenic cytokines enhance foam cell formation by enhancing modified LDL-C uptake and inhibiting proper reverse cholesterol transport in macrophages. Other kinds of cytokines, such as IL-13, IL-10, IL-19 and transforming growth factor-β (TGF-β), have been shown to reduce atherosclerosis [10] .
TNF-α and IFN-γ also contribute to macrophage and vascular smooth muscle cells (VSMCs) apoptosis, promoting the thinning of the fibrous cap and the growth of the necrotic core, whose progression is linked to the formation of cholesterol crystals in the cytosols, leading to inflammasome activation and subsequent IL-1α/β production [11] .
In addition, macrophages can contribute to oxidative stress through production of hydrogen peroxide, superoxides, neopterin and myeloperoxidases [12] .
These radicals can promote further oxidation of LDL-C within the plaques, as well as the triggering of endoplasmic reticulum (ER) stress that can initiate apoptosis. In contrast to atherogenic inflammatory responses, the atheroprotective cytokines IL-10, IL-19 and TGF-β reduce leukocyte recruitment and inflammation and slow down atherosclerosis progression [13] . Thus, the plaque may be considered as a dynamic environment in which plaque progression is the result of the balance between pro-inflammatory and atheroprotective cytokines.
In this regard, a pivotal role has been reported for soluble CD40 ligand (sCD40L), with particular reference to diabetic patients. Upregulation of sCD40L as a consequence of persistent hyperglycaemia in diabetic patients seems to result in EC activation and monocyte recruitment to the arterial wall, possibly contributing to accelerated atherosclerosis development in diabetes. In fact, elevated sCD40L levels have been associated with enhanced in vitro expression of adhesion molecules, impaired migration in ECs, enhanced O 2 -generation in monocytes and with higher HbA1c; vice versa, metabolic profile improvement has been associated with a reduction of plasma sCD40L [14] .
In addition to inflammation, endothelial cells at atherosusceptible sites show signs of enhanced cellular injury as a result of mechanical, oxidative and metabolic stress. Transcriptome analysis of endothelial cells at athero-susceptible sites suggests that ER stress may exert a pivotal role in atherogenic endothelial activation [15] .
ER stress is significant when protein rates overcome the ER's ability to promote proper protein folding. The accumulation of misfolded peptides initiates the unfolded protein response and this process results in an upregulation of ER chaperone proteins. ER stress plays a role in inflammation, oxidative stress and apoptosis [16] .
It has also been noted that disturbed flow promotes ER stress in endothelial cells and mimicking ER stress enhances atherosclerotic plaque formation in laminar flow regions [17] .
In contrast, laminar flow is known to reduce endothelial cell metabolism through Kruppel like factor 2 (Klf2)dependent repression of endothelial glycolytic enzymes [18] , eliciting in turn endothelial cell autophagy to protect endothelial cells from oxidant-induced cell injury [19] .
Moreover, oscillatory flow stimulates a c-Jun N-terminal kinase (JNK)-dependent increase in mitochondrial superoxide production limiting autophagy, thus accumulating oxidant injuries at sites of disturbed flow [20] .
PCSK9: An Actor Not to be Missed
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a fundamental regulator of LDL-C. Consistently, anti-PCSK9 monoclonal antibodies have been recently approved for the treatment of heterozygous familial hyper-cholesterolemia and clinical atherosclerotic cardiovascular disease as an addition to diet and maximally-tolerated statin therapy in adults who require additional LDL-C lowering [21] .
PCSK9 interacts with the LDL-C receptor (LDL-R) inducing its degradation by conveying it in lysosomes and blocking its recycling on the cytoplasmic membrane [22] .
Because PCSK9 induces the degradation of LDL-R, its pharmacological inhibition would prolong the duration of the receptor action, leading to a drastic reduction of LDL-C [23] .
Moreover, growing experimental and clinical evidence is widening our understanding of the mechanisms through which this protein may facilitate the genesis of atherosclerosis, independently of its impact on lipid metabolism [24] .
An increasingly emerging hypothesis suggests that the impact of PCSK9 on lipids and on atherosclerosis involves mechanisms going beyond the regulation of the clearance of the LDL-C: PCSK9, in fact, does not bind exclusively the LDL-R but promotes the degradation of other receptors such as the receptor of very low density lipoproteins (VLDL), CD36, ApoER2 and receptor of type 1 LDL (LRP1) [25, 26] , whose contribution to the homeostasis of cholesterol is still unclear, but seems to be linked to triglyceride-rich lipoprotein (TRL) metabolism. TRLs represent important elements in atherosclerosis development and the impact of PCSK9 on these highly pro-atherogenic particles provides an additional mechanism by which PCSK9 inhibitors can reduce the risk of atherosclerotic cardiovascular diseases.
PCSK9 has also been shown to provide other proatherosclerotic effects not exclusively linked to plasma concentrations of apoB-containing lipoproteins. Indeed, PCSK9 seems to be expressed in the atheromatous plaque and in particular at the level of VSMCs and in ECs, where it exerts paracrine effects on an array of foam cell receptors, including the LDL-R and CD36. This represents a potential mechanism to modulate atherogenesis independently of plasma LDL-C concentrations, although its impact on each of these foam cell receptors and its relevance to atherosclerosis remains unclear [27] .
PCSK9 released by VSMCs may influence the expression of the LDL-R on the surface of macrophages [28] . PCSK9 has been also shown to promote the inflammatory response in macrophages [29] .
The expression of PCSK9 in VSMCs appears to be influenced by shear stress. Moreover, in the absence of PCSK9, a protective effect has been observed on the formation of the neointima, after a vascular insult [30] .
An interesting relationship may also exist between PCSK9 and endothelial function. Indeed, treatment with a PCSK9 inhibitor may improve endothelial function in subjects with increased cardiovascular risk and this improvement is proportional to LDL-C reduction [31] .
One study reported an impressive improvement in carotid-femoral pulse wave velocity after short-term treatment with a PCSK9 inhibitor. This result was achieved despite an increase in LDL-C, suggesting that the PCSK9 inhibitors may exert a beneficial impact on vasomotor function independently of their lipid-lowering effect [32] .
Unexpectedly, given the body of evidence on endothelial function, studies performed until now have shown no correlation between PCSK9 and hypertension. Indeed, PCSK9−/− mice display normal sodium balance and blood pressure regulation [33] . Moreover, PCSK9 level is unrelated to blood pressure in Chinese hypertensive patients [34] . Larger studies are needed to better clarify the link between hypertension and PCSK9.
Another important element within the relationship between inflammation, PCSK9 and atherosclerosis is represented by the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) whose expression is increased by inflammation and that is involved in oxidized LDL-C uptake with a self-regulation mechanism with PCSK9, that induces LOX-1 transcription which in turn stimulates PCSK9 [35] . Furthermore, in an inflammatory context, high levels of PCSK9 potently stimulate the expression of LOX-1 and oxidized LDL-C uptake in macrophages and, moreover, PCSK9 has been shown to promote atherosclerosis directly through the modulation of proinflammatory monocytes in the arterial wall [36] .
In conclusion, PCSK9 appears to have pleiotropic actions and, consistently, the effect of anti-PCSK9 monoclonal antibodies may determine not only a strong reduction of LDL-C, but also other important effects in the atherosclerotic process, that are still the object of ongoing investigations.
micro-RNAs: The Directors Behind the Scene of Atherosclerosis
MicroRNAs (miRNAs) play a key role in the context of the crosstalk between endothelium and cholesterol [37] (Fig. 1) .
MiRNAs are short non-coding RNA molecules (about 18-24 nucleotides), exerting their function via the seed region, a sequence of 6-8 nucleotides that binds to messenger ribonucleic acid (mRNA) [38] identified over 25 years ago [39] . This interaction with mRNA often results in the prevention of protein production by different mechanisms.
Both hyperlipidemia and shear stress are two important pathogenetic elements in the vessel wall in terms of atherosclerotic lesion formation. When stimulated by biochemical and biomechanical stimuli, endothelial cells undergo a series of molecular and cellular conformational changes promoting atherogenesis. First of all, early induction of adhesion molecule expression such as vascular cell adhesion molecule (VCAM)-1, intracellular adhesion molecule (ICAM)-1 and E-selectin facilitates leukocyte recruitment to the vessel wall and may be among the earliest hallmarks associated with nascent plaques [40] .
A lot of miRNAs have been implicated in atherogenesis thanks to the possibility to target the 3′-UTRs of these molecules such as miR-17-3p, targeting ICAM-1, and miR-31, targeting E-selectin [41] .
MiRNAs, Endothelium and Inflammation
MiR-92a is expressed in ECs and is dynamically regulated by shear stress both in vitro and in vivo [42] . When comparing in vivo athero-prone areas of the aortic arch with atheroresistant regions, miR-92a expression has been found highly induced in the first ones [43] .
In the context of the dynamic relation between endothelium and physical forces that act within the vessels, a large number of miRNAs, such as miR-126, miR-10a, miR-19a, Fig. 1 Summary of the influence of PCSK9 and hypercholesterolemia on the relationship between endothelium and lipids. In this context, also microRNAs, shear stress and inflammation play an important role miR-23b, miR-21, miR-663, miR-143/145, miR-101, miR-712, miR-205, miR-155, 146a and miR-181b seem to have a role as mechano-miRNAs. These mechano-miRNAs mainly target key signaling pathways involved in endothelial cells cycle, inflammation, apoptosis and NO signaling [44] .
Moreover, miR-126 is one of the most widely expressed miRNAs in the endothelium and it has been shown to play a crucial role in regulating inflammation and angiogenesis [45] .
In fact, miR-126 has been involved in endothelial dysfunction itself, by reducing VCAM-1 expression and thereby leucocyte homing in the arteries, thus modulating, through different pathways, vascular inflammation [46] .
A similar role in the regulation of vascular inflammation is played by miR-155 and miR-221/222 through NOS regulation [47] .
Moreover, miR-155 increased untreated monocyte adhesion to aortic endothelial cells by promoting ICAM-1 expression during homeostasis and lipopolysaccharides (LPS)-induced inflammation [48] .
On the contrary, a number of miRNAs with anti-inflammatory properties has been identified. For example, miR-10a is expressed in endothelial cells where it seems to contrast pro-inflammatory gene expression in athero-susceptible regions in vivo, thus exerting a possible atheroprotective role [49] .
MiRNAs, Liver and Cholesterol Metabolism
In addition to modulate inflammation, miRNAs are also involved in cholesterol homeostasis by controlling LDL-C and high density lipoprotein cholesterol (HDL-C) abundance.
Since the liver has a key role in the production and clearance of lipoproteins, a great number of hepatic-enriched miRNAs have been identified that functionally regulate lipoprotein metabolism. First of all, miR-122 has been implicated in lipoprotein metabolism. Studies based on loss-of-function experiments in animals, identified miR-122 as a crucial regulator of cholesterol and lipoprotein homeostasis [50] .
In addition, miR-223 and miR-27b have been identified as post-transcriptional regulatory hubs involved in the control of cholesterol and lipoprotein metabolism genes [51, 52] . Concerning miR-223, it represses genes involved in cholesterol biosynthesis (HMGS1, SC4MOL) and HDL-C uptake (SRB1) [51] , whereas miR-27b represses a number of targets (PPARG , GPAM, ANGPTL3 and NDST1) involved in lipoprotein metabolism and remodeling [52] .
MiRNA regulation of plasma levels of LDL-C through targeting of the LDL-R has also been reported. LDL-R expression in the liver promotes the clearance of circulating LDL-C particles and is a major determinant of plasma cholesterol levels. MiRNAs are also involved in the regulation of LDL-C plasma levels: miR-148a is a negative regulator of expression and activity of LDL-R, that usually promotes the clearance of circulating LDL-C particles [53] .
MiRNAs have also been reported to act as critical regulators of HDL-C biogenesis and cholesterol efflux. In fact, a great number of miRNAs (miR-33 [54] , miR-758 [55] , miR-26 [56] , miR-106 [57] , miR-144 [58] ) have been shown to target ABCA1 to reduce cholesterol efflux to apoA1 in vitro. MiR-33 inhibition in mouse models of atherosclerosis plays a pivotal role in the modulation of circulating HDL-C and regression of atherosclerosis. Targeted deletion of miR-33 increased plasma levels of HDL-C and reduced atherosclerotic plaque size in Apoe −/− mice and furthermore treatment of Ldlr −/− mice increased plasma levels of HDL-C associated with a regression of atherosclerosis [59] .
MiRNAs have also been implicated in macrophage cholesterol efflux in stable plaque. In fact, adenosine triphosphate (ATP)-binding cassette (ABC) transporters A1 and G1 are the main transporters involved in this process and we showed that miR-758 and miR-33b are potential modulators of ABCA1 expression in atherosclerotic plaques [60] .
MiRNAs and Atherosclerotic Plaques
MiRNAs have been also implicated in plaque instability and related cardiovascular events, such as stroke and myocardial infarction. We demonstrated that profound differences exist in the expression of 5 miRNAs (miR-100, mi-127, miR-145, miR-133a, and miR-133b) in symptomatic versus asymptomatic plaques. These data were confirmed by in vitro experiments on endothelial cells transfected with miR-145 and miR-133a that further remarked the importance of these miRNAs in the modulation of stroke-related proteins [61] .
Moreover, hypertension may upregulate miR-145 expression in human atherosclerotic plaques [62] .
In light of all these data, it seems clear that miRNAs represent crucial messengers of the fascinating dialogue between endothelium and lipids. This relation has attracted the attention of researchers and it will continue to deepen our knowledge, thanks to further studies, with important implications in terms of diagnosis and therapies for our patients.
Conclusions and Perspectives
Advances in experimental research, with development of high throughput techniques, have led, over the last century, to a tremendous progress in the understanding and fine tuning of the molecular mechanisms leading to atherosclerosis. Identification of pivotal keystone molecules bridging lipid metabolism, endothelial dysfunction and atherogenesis, such as LOX-1, PCSK9 and others, are emerging as valuable target for prediction, prevention and treatment of atherosclerosis-related disease.
Intensive LDL-C lowering, achieved through the combined therapy with PCSK9 antibody and statin, has been associated with coronary plaque regression in a patient with double-heterozygous familial hypercholesterolemia with a LDL-R mutation and a PCSK9 V4I mutation. This finding provides the mechanistic framework for studies assessing the efficacy of combined therapy including PCSK9 antibodies in reducing cardiovascular events in patients with established cardiovascular disease [63] .
The existence of a functional miRNAs machinery in human cells have deepen our knowledge about the molecular phenotype in health and disease, and opens up the possibility of modulating gene expression using therapeutic RNAs to prevent atherogenesis [64] .
An additional layer of complexity has been provided, over the last 10 years, by the publication of large-scale genomewide association studies (GWAS), identifying dozens of candidate genetic loci associated with risk for coronary artery disease (CAD). Indeed, genetics accounts for approximately 50% heritability of CAD. Since the role and function of identified loci or genes remains often elusive, this kind of studies has promoted a novel wave of functional studies to translate GWAS findings into novel discoveries involving the pathogenesis of atherosclerosis and atherothrombosis. In this regard, the novel GWAS-identified CAD risk gene CAD/ KIAA1462 has been shown to promote endothelial dysfunction and atherosclerosis. Indeed, junctional protein JCAD triggers the expression of inflammatory genes in endothelial cells, driving an inflammatory process via the recruitment of monocytes and resulting in the formation of atherosclerotic plaques in ApoE−/− mice [65] . This approach, starting from the genetic loci associated with the risk of disease and moving back to the pathophysiology, has also therapeutic implications. Indeed, targeting GWAS-identified genes relevant to cardiovascular disease, such as JCAD, may represent a novel strategy for designing innovative drugs to prevent or delay atherosclerosis and thrombosis.
